abstract |
A pharmaceutically acceptable formulation of cannabinoid for non-oral delivery. The formulation including at least one cannabinoid at 0.05% to 50% by weight of the total formulation. The formulation being delivered to a patient to alleviate symptoms including, but not limited to, pain, nausea, vomiting, and the like. |